Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies
Frontiers in Bioengineering and Biotechnology · 09.06.2025 · 13
DOI: 10.3389/fbioe.2025.1604502 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 09.06.2025. Verfasst von Rachel Santana Cunha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
Spinal cord injury (SCI) is a debilitating condition that leads to permanent neurological deficits due to the formation of a glial scar and the accumulation of chondroitin sulfate proteoglycans (CSPGs), which inhibit axonal regeneration. Chondroitinase ABC (ChABC), a bacterial enzyme capable of degrading CSPGs, has emerged as a promising therapeutic strategy for enhancing neural plasticity and functional recovery after SCI. However, clinical translation remains challenging due to the enzyme’s thermal instability, short half-life, and limited penetration into the lesion site. This review provides a comprehensive overview of current strategies for ChABC delivery, including direct infusion, nanoparticles, hydrogels, scaffolds, viral vectors, and stem cell-based approaches. We highlight recent technological advances that improve enzyme stability, targeting, and sustained release, as well as combinatorial therapies that enhance tissue regeneration. Although ChABC monotherapy has shown limited efficacy, its association with other regenerative approaches has demonstrated significant potential in preclinical models. Finally, we discuss the translational challenges and future directions required to bring ChABC-based therapies closer to clinical application in SCI patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Biotechnology and Cell Therapy, São Rafael Hospital, Salvador, Bahia, Brazil.
- CBTC, D´Or Institute for Research and Education (IDOR), Salvador, Brazil.
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Rio de Janeiro, Bahia, Brazil.
- Pioneer Science Initiative, D'Or Institute for Research and Education (IDOR), Rio de Janeiro, Brazil.
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Cunha, R. S., Rossi, E. A., de Santana, T. A., Costa-Ferro, Z. S. M., & Souza, B. S. F. (2025). Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies. Frontiers in Bioengineering and Biotechnology, 13. https://doi.org/10.3389/fbioe.2025.1604502
Vancouver
Cunha RS, Rossi EA, de Santana TA, Costa-Ferro ZSM, Souza BSF. Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies. Frontiers in Bioengineering and Biotechnology. 2025;13. doi:10.3389/fbioe.2025.1604502
BibTeX
@article{Cunha2025,
author = {Cunha, Rachel Santana and Rossi, Erik Aranha and de Santana, Thaís Alves and Costa-Ferro, Zaquer Suzana Munhoz and Souza, Bruno Solano de Freitas},
title = {Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies},
journal = {Frontiers in Bioengineering and Biotechnology},
year = {2025},
volume = {13},
doi = {10.3389/fbioe.2025.1604502}
}
EUVIMED